Costo y beneficio de la inmunización contra la rubéola: revisión sistemática

Abstract

Background: Rubella is a disease caused by an RNAtype virus, which belongs to the Rubivirus genus of the Togaviridae family. The vaccine to prevent this pathology is called the triple viral vaccine, because it also protects against measles and mumps. Objective: To analyze the cost-benefit of vaccination against rubella. Methodology: For which a systematic review was carried out, through the search for scientific documents in reliable databases: Scopus, Web of Science and PubMed. The inclusion criteria were: original articles and systematic reviews of the last thirty-two years. While, the exclusion criteria: documents without free access, articles in which their area of study is not related to the life sciences. Data collection was carried out systematically, using the PRISMA statement, in order to avoid omissions. Results: The authors agreed that immunization against rubella results in cost savings for health systems, associated with a decrease in morbidity and mortality rates. However, the study in the United States determined that there is no direct relationship between saving resources and rubella immunization. Conclusion: Immunization against rubella results in cost savings, especially in low-income countries and where there is a higher risk of acquiring the pathology.